Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis.

[1]  R. Kaddoura,et al.  Revisiting beta-blocker therapy in heart failure with preserved ejection fraction. , 2023, Current problems in cardiology.

[2]  N. Desai,et al.  Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis , 2022, Cardiology in review.

[3]  A. Mahabadi,et al.  Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction. , 2022, International journal of cardiology.

[4]  Ruiqi Zhang,et al.  Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction , 2022, JAMA network open.

[5]  J. Hankins,et al.  The Efficacy of Various Pharmacological Agents on Long-Term Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Randomized Control Trials , 2022, Cureus.

[6]  Thomas A. Slater,et al.  Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction , 2022, Clinical Research in Cardiology.

[7]  J. Núñez,et al.  Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. , 2022, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[8]  M. Ishii,et al.  Beta-blockers are associated with increased B-type natriuretic peptide levels differently in men and women in heart failure with preserved ejection fraction , 2022, American Journal of Physiology-Heart and Circulatory Physiology.

[9]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[10]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[11]  N. Thilly,et al.  Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study , 2021, European Journal of Clinical Pharmacology.

[12]  L. Lund,et al.  Association between ß-Blockers and Outcomes in HFpEF - Current Insights from the SwedeHF Registry. , 2021, Journal of cardiac failure.

[13]  E. Mayo-Wilson,et al.  PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.

[14]  N. Ohte,et al.  Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials , 2020, Heart Failure Reviews.

[15]  D. Harada,et al.  The impact of right ventricular dysfunction on the effectiveness of beta-blockers in heart failure with preserved ejection fraction. , 2020, Journal of cardiology.

[16]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[17]  L. C. Davies,et al.  Do beta-blockers and inhibitors of the renin–angiotensin aldosterone system improve outcomes in patients with heart failure and left ventricular ejection fraction >40%? , 2019, Heart.

[18]  J. Hanlon,et al.  Indications for β‐Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction , 2019, Journal of the American Geriatrics Society.

[19]  Deepak L. Bhatt,et al.  Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. , 2018, The American journal of medicine.

[20]  Y. Lopatin.  Heart Failure with Mid-Range Ejection Fraction and How to Treat It. , 2018, Cardiac failure review.

[21]  N. Chaiyakunapruk,et al.  Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison , 2018, Heart failure reviews.

[22]  A. Shah,et al.  Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis , 2017, Heart.

[23]  R. Lumbers,et al.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. , 2017, The Cochrane database of systematic reviews.

[24]  N. Shafiq,et al.  Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial , 2017, Perspectives in clinical research.

[25]  N. Ohte,et al.  The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies. , 2017, International journal of cardiology.

[26]  M. Escobar,et al.  Prognosis of heart failure with preserved ejection fraction treated with β-blockers: A propensity matched study in the community. , 2016, International journal of cardiology.

[27]  A. Sinha,et al.  Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. , 2016, Cardiovascular therapeutics.

[28]  Yang Zhang,et al.  Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study , 2016, European journal of preventive cardiology.

[29]  M. Vaduganathan,et al.  Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review , 2016, European journal of heart failure.

[30]  R. McKelvie,et al.  The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). , 2015, JACC. Heart failure.

[31]  G. Sayer,et al.  Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction , 2015, Current opinion in cardiology.

[32]  F. Messerli,et al.  Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis , 2015, Heart Failure Reviews.

[33]  G. Biondi-Zoccai,et al.  Heart failure with preserved ejection fraction: refocusing on diastole. , 2015, International journal of cardiology.

[34]  F. Liu,et al.  Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis , 2014, PloS one.

[35]  J. Spertus,et al.  Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. , 2013, Journal of cardiac failure.

[36]  M. Hori,et al.  Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J‐DHF) , 2013, European journal of heart failure.

[37]  M. D. de Wit,et al.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions , 2012, Annals of the rheumatic diseases.

[38]  V. Novack,et al.  Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure. , 2012, European journal of internal medicine.

[39]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[40]  M. Escobar,et al.  Mortality and morbidity of newly diagnosed heart failure with preserved systolic function treated with β-blockers: a propensity-adjusted case-control populational study. , 2011, International journal of cardiology.

[41]  J. Ge,et al.  Rationale and design of the β‐blocker in heart failure with normal left ventricular ejection fraction (β‐PRESERVE) study , 2010, European journal of heart failure.

[42]  S. Najjar,et al.  Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. , 2010, The American journal of cardiology.

[43]  M. Whooley,et al.  Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study). , 2010, The American journal of cardiology.

[44]  A. Cohen-Solal,et al.  Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.

[45]  E. Schwarz,et al.  Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. , 2009, The American journal of cardiology.

[46]  J. Foody,et al.  Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. , 2008, The American journal of cardiology.

[47]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[48]  J. González-Juanatey,et al.  Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. , 2006, Journal of cardiac failure.

[49]  D. Sane,et al.  Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report , 2005, Circulation.

[50]  B. Andersson,et al.  Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC) , 2004, European journal of heart failure.

[51]  A. Rigby,et al.  Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.

[52]  G. He,et al.  Short-Term and Long-Term Effects of Bisoprolol on Chronic Heart Failure Related to Rheumatic Heart Disease and Atrial Fibrillation , 2005 .